Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Denosumab for Skeletal Disease in Type 2 Diabetes
NCT03457818Phase 2Terminated
- Start
- Nov 2018
- Primary completion
- Jun 2020
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of denosumab in osteoporosis (2 arms). Primary endpoint: Change in Cortical Porosity (Ct.Po) at 12 months. Started Nov 2018; status: terminated.
02
Drugs
denosumab
03
Conditions
osteoporosis
Beyond the preview
Go deeper on NCT03457818.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03457818.